a Alexion Pharmaceuticals Inc. , Cambridge MA.
b Alexion Pharmaceuticals Inc. , New Haven CT.
RNA Biol. 2018;15(6):756-762. doi: 10.1080/15476286.2018.1450054. Epub 2018 Mar 26.
mRNA based therapies hold great promise for the treatment of genetic diseases. However, this therapeutic approach suffers from multiple challenges including the short half-life of exogenously administered mRNA and subsequent protein production. Modulation of untranslated regions (UTR) represents one approach to enhance both mRNA stability and translation efficiency. The current studies describe and validate screening methods using a diverse set of 5'UTR and 3'UTR combinations for improved expression of the Arginase 1 (ARG1) protein, a potential therapeutic mRNA target. Data revealed a number of critical aspects which need to be considered when developing a screening approach for engineering mRNA improvements. First, plasmid-based screening methods do not correlate with protein expression driven by exogenously expressed mRNA. Second, improved ARG1 protein production was driven by increased translation and not improved mRNA stability. Finally, the 5' UTR appears to be the key driver in protein expression for exogenously delivered mRNA. From the testing of the combinatorial library, the 5'UTR for complement factor 3 (C3) and cytochrome p4502E1 (CYP2E1) showed the largest and most consistent increase in protein expression relative to a reference UTR. Collectively, these data provide important information for the development and optimization of therapeutic mRNAs.
mRNA 疗法在治疗遗传疾病方面具有巨大的潜力。然而,这种治疗方法存在多个挑战,包括外源性 mRNA 的半衰期短和随后的蛋白质产生。调节非翻译区(UTR)是提高 mRNA 稳定性和翻译效率的一种方法。目前的研究描述并验证了使用多种 5'UTR 和 3'UTR 组合的筛选方法,以提高精氨酸酶 1(ARG1)蛋白的表达,ARG1 蛋白是一种有潜力的治疗性 mRNA 靶标。数据揭示了在开发用于工程 mRNA 改进的筛选方法时需要考虑的一些关键方面。首先,基于质粒的筛选方法与由外源性表达的 mRNA 驱动的蛋白质表达不相关。其次,ARG1 蛋白产量的提高是由翻译增加而不是 mRNA 稳定性提高驱动的。最后,5'UTR 似乎是对外源递送至的 mRNA 进行蛋白质表达的关键驱动因素。从组合文库的测试中,补体因子 3(C3)和细胞色素 p4502E1(CYP2E1)的 5'UTR 相对于参考 UTR 显示出最大和最一致的蛋白质表达增加。总之,这些数据为治疗性 mRNA 的开发和优化提供了重要信息。